CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE
Cumberland Pharmaceuticals (Nasdaq: CPIX) has scheduled its Q1 2025 financial results announcement and company update for Tuesday, May 6, 2025, after market close. A conference call will follow at 4:30 p.m. Eastern Time.
The specialty pharmaceutical company focuses on unique products across three key segments: hospital acute care, gastroenterology, and oncology. Their FDA-approved portfolio includes:
- Acetadote® for acetaminophen poisoning
- Caldolor® for pain and fever
- Kristalose® for constipation
- Sancuso® for chemotherapy-related nausea
- Vaprisol® for hyponatremia
- Vibativ® for bacterial infections
The company is also conducting Phase II clinical trials of ifetroban for multiple conditions, including Systemic Sclerosis, Duchenne Muscular Dystrophy cardiomyopathy, and Idiopathic Pulmonary Fibrosis.
Cumberland Pharmaceuticals (Nasdaq: CPIX) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per martedì 6 maggio 2025, dopo la chiusura del mercato. Seguirà una conferenza telefonica alle 16:30 ora della costa orientale.
Questa azienda farmaceutica specializzata si concentra su prodotti unici in tre segmenti chiave: assistenza ospedaliera acuta, gastroenterologia e oncologia. Il loro portafoglio approvato dalla FDA include:
- Acetadote® per il trattamento dell'avvelenamento da acetaminofene
- Caldolor® per il dolore e la febbre
- Kristalose® per la stitichezza
- Sancuso® per la nausea correlata alla chemioterapia
- Vaprisol® per l'iponatriemia
- Vibativ® per le infezioni batteriche
L'azienda sta inoltre conducendo studi clinici di Fase II su ifetroban per diverse condizioni, tra cui sclerosi sistemica, cardiomiopatia da distrofia muscolare di Duchenne e fibrosi polmonare idiopatica.
Cumberland Pharmaceuticals (Nasdaq: CPIX) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización de la compañía para el martes 6 de mayo de 2025, después del cierre del mercado. Posteriormente, se realizará una llamada conferencia a las 4:30 p.m. hora del Este.
Esta empresa farmacéutica especializada se enfoca en productos únicos en tres segmentos clave: atención hospitalaria aguda, gastroenterología y oncología. Su portafolio aprobado por la FDA incluye:
- Acetadote® para intoxicación por acetaminofén
- Caldolor® para dolor y fiebre
- Kristalose® para el estreñimiento
- Sancuso® para náuseas relacionadas con la quimioterapia
- Vaprisol® para hiponatremia
- Vibativ® para infecciones bacterianas
La compañía también está llevando a cabo ensayos clínicos de fase II con ifetroban para varias condiciones, incluyendo esclerosis sistémica, miocardiopatía de la distrofia muscular de Duchenne y fibrosis pulmonar idiopática.
Cumberland Pharmaceuticals (나스닥: CPIX)는 2025년 5월 6일 화요일 시장 마감 후 2025년 1분기 재무 실적 발표 및 회사 업데이트를 예정하고 있습니다. 이후 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜이 진행됩니다.
이 전문 제약회사는 병원 급성 치료, 위장병학, 종양학의 세 가지 주요 부문에서 독특한 제품에 집중하고 있습니다. FDA 승인 포트폴리오에는 다음이 포함됩니다:
- Acetadote® - 아세트아미노펜 중독 치료제
- Caldolor® - 통증 및 발열 치료제
- Kristalose® - 변비 치료제
- Sancuso® - 화학요법 관련 구역질 치료제
- Vaprisol® - 저나트륨혈증 치료제
- Vibativ® - 세균 감염 치료제
또한, 회사는 전신 경화증, 뒤쉔 근이영양증 심근병증, 특발성 폐섬유증 등 여러 질환에 대해 ifetroban의 2상 임상시험을 진행 중입니다.
Cumberland Pharmaceuticals (Nasdaq : CPIX) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 ainsi qu'une mise à jour de l'entreprise pour le mardi 6 mai 2025, après la clôture du marché. Une conférence téléphonique suivra à 16h30, heure de l'Est.
Cette société pharmaceutique spécialisée se concentre sur des produits uniques dans trois segments clés : soins aigus hospitaliers, gastro-entérologie et oncologie. Leur portefeuille approuvé par la FDA comprend :
- Acetadote® pour l'intoxication au paracétamol
- Caldolor® pour la douleur et la fièvre
- Kristalose® pour la constipation
- Sancuso® pour les nausées liées à la chimiothérapie
- Vaprisol® pour l'hyponatrémie
- Vibativ® pour les infections bactériennes
L'entreprise mène également des essais cliniques de phase II sur l'ifétroban pour plusieurs affections, notamment la sclérodermie systémique, la cardiomyopathie liée à la dystrophie musculaire de Duchenne et la fibrose pulmonaire idiopathique.
Cumberland Pharmaceuticals (Nasdaq: CPIX) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 sowie ein Unternehmensupdate für Dienstag, den 6. Mai 2025, nach Börsenschluss geplant. Anschließend findet um 16:30 Uhr Eastern Time eine Telefonkonferenz statt.
Das spezialisierte Pharmaunternehmen konzentriert sich auf einzigartige Produkte in drei wichtigen Segmenten: akute Krankenhausversorgung, Gastroenterologie und Onkologie. Ihr von der FDA zugelassenes Portfolio umfasst:
- Acetadote® zur Behandlung von Paracetamolvergiftungen
- Caldolor® gegen Schmerzen und Fieber
- Kristalose® bei Verstopfung
- Sancuso® gegen durch Chemotherapie bedingte Übelkeit
- Vaprisol® bei Hyponatriämie
- Vibativ® zur Behandlung bakterieller Infektionen
Das Unternehmen führt außerdem Phase-II-Studien mit Ifetroban für verschiedene Erkrankungen durch, darunter systemische Sklerose, Duchenne-Muskeldystrophie-Kardiomyopathie und idiopathische Lungenfibrose.
- Diverse FDA-approved product portfolio across multiple market segments (hospital acute care, gastroenterology, oncology)
- Active R&D pipeline with Phase II clinical programs for ifetroban in three different conditions
- Strong market position with 6 FDA-approved branded products
- None.
A conference call will be held on May 6 at 4:30 p.m. Eastern Time to discuss the results and update.
The link to register is: https://register-conf.media-server.com/register/BIea2bc7f82dd24caea135dbe5460d9b6f.
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting https://edge.media-server.com/mmc/p/wost2na9/.
Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The Company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
The company's portfolio of FDA-approved brands includes:
- Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor® (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Sancuso® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at www.cumberlandpharma.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-q1-2025-financial-results--company-update-302441751.html
SOURCE Cumberland Pharmaceuticals Inc.
FAQ
When will Cumberland Pharmaceuticals (CPIX) release Q1 2025 earnings?
How can investors join Cumberland Pharmaceuticals (CPIX) Q1 2025 earnings call?
What FDA-approved products does Cumberland Pharmaceuticals (CPIX) currently market?
What clinical trials is Cumberland Pharmaceuticals (CPIX) currently conducting?
How long will Cumberland Pharmaceuticals' (CPIX) Q1 2025 earnings call replay be available?
